Companies / X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc
Nasdaq: XFORCIK 1501697BOSTON, MA
Financials · FY2025
Ownership
99.1M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 0.18% | 176,293 |
| 10%+ / strategic | 8.57% | 8,499,100 |
| Institutions | 85.47% | 84,740,431 |
| Public float | 5.78% | 5,730,919 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 5
View all →| Insider | % of shares | Shares |
|---|---|---|
Kirske DavidChief Financial Officer | 0.18% | 176,293 |
Bridger GaryDirector | — | — |
de Craecker FrancoiseFormerDirector | — | — |
Stewart MurrayDirector | — | — |
Wyzga Michael SDirector | — | — |
Institutional holders 78
View all →| Holder | Value | % of shares |
|---|---|---|
| $35.80M | 9.03% | |
| $34.00M | 8.57% | |
| $32.83M | 8.28% | |
| $31.87M | 8.04% | |
| $27.83M | 6.80% | |
| $25.94M | 5.60% | |
| $23.20M | 5.85% | |
| $20.05M | 5.06% | |
| $14.89M | 3.75% | |
| $13.69M | 3.45% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | Kirske David Executive | Sell | Common Stock | $72.8K | -17K -8.78% | 176,293 0.18% of shares | low |
| Jan 1, 2026 | Stewart Murray Director | Grant | Stock Option (right to buy) | — | +110K | 0 0.00% of shares | low |
| Jan 1, 2026 | Bridger Gary Director | Grant | Stock Option (right to buy) | — | +110K | 0 0.00% of shares | low |
| Jan 1, 2026 | de Craecker Francoise Director | Grant | Stock Option (right to buy) | — | +110K | 0 0.00% of shares | low |
| Jan 1, 2026 | Wyzga Michael S Director | Grant | Stock Option (right to buy) | — | +110K | 0 0.00% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Empery Asset Management, LP | Passive13G/A | — |
| Nantahala Capital Management, LLC | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| Bain Capital Life Sciences Fund, L.P. | Passive13G/A | — |
| Trails Edge Capital Partners, LP | Passive13G/A | — |
| Morgan Stanley | Passive13G/A | — |
| Morgan Stanley | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| XFOR | — | 98420X202 |